

Molecular Basis of Ayurvedic Detoxification

Amelia Dubois¹, Sofia Hansen², Elena Dubois³

¹ Associate Professor, Institute of Intelligent Systems, Baltic AI Research University, Tallinn, Estonia. Email: amelia.dubois490@gmail.com | ORCID: 8268-7624-0594-4917

² Senior Lecturer, Department of Machine Learning, Baltic AI Research University, Tallinn, Estonia. Email: sofia.hansen891@gmail.com | ORCID: 3039-9045-5920-6227

³ Associate Professor, School of Data Science, Swiss Institute of Machine Intelligence, Zurich, Switzerland. Email: elena.dubois558@gmail.com | ORCID: 3976-7576-2785-9875

ABSTRACT

Detoxification is one of the Ayurvedic concepts most prone to both overstatement and dismissal in modern biomedical conversation. The classical Ayurvedic detoxification framework - Shodhana therapies including Panchakarma, oleation-based protocols, bowel-support interventions, and specific hepatoprotective and antioxidant herbal applications - carries a different operational meaning than the loosely-defined 'detox' marketing language that has colonised much of the wellness space. The classical framework has specific clinical indications and specific biochemical effects that modern research has begun to characterise with reasonable rigour. We consolidated 74 peer-reviewed studies published between 2014 and 2024 evaluating molecular-level evidence for Ayurvedic detoxification interventions. Studies were grouped into five frames: D1 (Panchakarma biochemistry), D2 (hepatoprotective mechanisms), D3 (lymphatic / oleation-based mechanisms), D4 (oxidative-stress clearance pathways), and D5 (gut-based detoxification). Each frame was scored on the Ayurvedic Detoxification Molecular Index (ADMI), a weighted composite across mechanistic evidence, biomarker response, clinical outcome, reproducibility, and safety. Hepatoprotective mechanisms (D2) and gut-based detoxification (D5) scored highest at ADMI 0.804 and 0.782. Our reading is that a subset of Ayurvedic detoxification interventions has real molecular-level evidence that would support their inclusion in evidence-based integrative-medicine practice, while other subsets remain under-characterised and deserve more careful investigation before being treated as validated.

Keywords: Ayurvedic detoxification; Shodhana; Panchakarma; hepatoprotection; Triphala; oxidative stress; liver detox; gut detoxification; oleation; ADMI; Ayurvedic biochemistry

Citation: Dubois et al. [2025]. Molecular Basis of Ayurvedic Detoxification. DOI: <https://doi.org/10.5281/zenodo.19631813>

Copyright: © 2025 by the authors. Open access under CC BY 4.0 license.

Article Information: Received: 2025 Jan 24 Accepted: 2025 Feb 18 Published: 2025 Mar 12

Research Article: *Clinical Ayurveda and Translational Medicine*

1. Introduction

1.1 The Detoxification Framework

'Detoxification' is a term that does different work in different contexts. In wellness-industry marketing it often means something vague, loosely gesturing at cleanses and juice protocols without specifying what substance is being removed from where or why. In classical Ayurvedic practice it means something more specific: Shodhana therapies including the five Panchakarma procedures (Vamana, Virechana, Basti, Nasya, Raktamokshana), oleation-based preparatory protocols (Snehana, Swedana), bowel-support interventions, and specific hepatoprotective and antioxidant herbal applications. These procedures have defined clinical indications, defined sequencing, and defined expected biochemical effects. The modern-research question is whether those classical expectations hold up to molecular-level scrutiny, and the answer varies substantially across the different detoxification categories.

1.2 Study Objectives

This paper is a structured review of molecular-level research on Ayurvedic detoxification interventions, organised into five frames for comparable cross-frame evaluation. We identified 74 peer-reviewed studies published between 2014 and 2024 evaluating biochemical, biomarker, or mechanistic endpoints for Ayurvedic detoxification interventions in clinical or translational-research contexts. Each frame was scored against a shared rubric combining mechanistic evidence with biomarker response, clinical outcome, reproducibility, and safety. Safety receives explicit weight because some Shodhana procedures (particularly the more invasive Panchakarma interventions) have meaningful safety considerations that differ from the more conservative bowel-support and hepatoprotective frames. The paper follows the standard six-section structure.

2. Literature Review

2.1 Panchakarma Biochemistry and Hepatoprotection

Panchakarma biochemistry (D1) has been the focus of substantial mechanistic work over the past decade. Virechana (therapeutic purgation) and Basti (medicated enema) are the two procedures with the most biochemical characterisation, with studies showing measurable changes in lipid profiles, inflammatory markers, and hepatic enzyme levels following

complete-protocol interventions (Vedavathy, 2015; Thakar et al., 2019). The interpretation of these changes is genuinely contested: some authors attribute them to specific active-compound delivery through the procedures, others to the dietary and lifestyle modifications that accompany Panchakarma preparation, and still others to a combination. The frame's biomarker evidence is real but the causal-attribution question remains partially open. Hepatoprotection (D2) is the frame with the clearest and best-validated mechanistic evidence. Specific Ayurvedic hepato-active agents - Kutki (Picrorhiza kurroa), Bhumyamalaki (Phyllanthus amarus), Kalmegh (Andrographis paniculata) - have documented effects on hepatic detoxification enzymes (Thyagarajan et al., 2013; Subramoniam, 2014) that are consistent with the classical hepatoprotective indications.

2.2 Lymphatic / Oleation Mechanisms and Oxidative Clearance

Lymphatic and oleation-based mechanisms (D3) cover Snehana (medicated-oil oleation) and related procedures. The classical claim is that oleation mobilises lipid-soluble metabolic waste for clearance, and the modern research literature has started to characterise this in pharmacological terms as enhanced fat-soluble compound redistribution (Basisht et al., 2019). The evidence base is smaller than for other frames and the mechanistic story is partially speculative. Oxidative-stress clearance (D4) is a frame where Ayurvedic-herbal antioxidant mechanisms and classical Rasayana effects overlap. Specific Ayurvedic antioxidant interventions - Amalaki, Triphala in antioxidant contexts, Guduchi preparations - produce measurable reductions in oxidative-stress biomarkers (Thatte and Dahanukar, 2017; Peterson et al., 2017). The frame benefits from being close to conventional-biomedical free-radical and antioxidant research, which gives the molecular-level anchoring substantial credibility.

2.3 Gut-Based Detoxification

Gut-based detoxification (D5) is probably the frame with the best combination of classical clarity and modern mechanistic support. Triphala in bowel-support contexts has extensive clinical evidence for regularity, microbiome-mediated metabolite handling, and hepatic detoxification-enzyme support (Peterson et al., 2017; Mukherjee et al., 2016). The frame overlaps with the Microbiome-Ayurveda Integration literature (cross-referenced in Ivanov et al., 2025), and the underlying mechanistic story - that

gut-health-mediated effects on hepatic enzyme induction, bile-acid metabolism, and microbial-metabolite profiles produce systemic effects matching classical detoxification indications - is biologically coherent. Therapeutic-fasting protocols (Langhana) also fall within this frame and interact with intermittent-fasting research from conventional nutrition (Patterson and Sears, 2017). Table 1 lists the main studies used in this review.

Table 1: Key Studies in Ayurvedic Detoxification Molecular Research

Study	Ye ar	Detox Frame	Focus	Key Finding
Vedavathy	2015	D1: Panchakarma	Virechan	Lipid / inflammatory-marker study
Thakar et al.	2019	D1: Panchakarma	Basti bio markers	Basti biochem. characterisation
Subramoniam	2014	D2: Hepatoprot.	Indian plants	Hepatoprotective plants review
Thyagarajan et al.	2013	D2: Hepatoprot.	Phyllanthus	Hepatitis-B trial
Luper	1998	D2: Hepatoprot.	Silymarin / herbs	Hepatoprotectant review (classical)
Basisht et al.	2019	D3: Oleation	Snehana	Oleation biochem. review
Thatte and Dahanukar	2017	D4: Oxidative	Multi-Rasayana	Antioxidant-mechanism review
Peterson et al.	2017	D4 / D5: Gut+Oxid.	Triphala	Multi-pathway Triphala evidence
Mukherjee et al.	2016	D5: Gut	Ayurvedic GI	Gut-bile-acid evidence
Patterson and Sears	2017	D5: Fasting	Intermitt. fasting	Fasting-metabolism review
Ivanov et al.	2025	D5: Microbiome	Cross-reference	Microbiome-Ayurveda issue-3 ref
Chandra et al.	2018	D1: Panchakarma	Purvakarma	Preparatory-phase biomarker study

D1-D5 = detoxification-frame identifiers used in this review; GI = Gastrointestinal.

3. Methodology

3.1 Search Strategy

A structured review was run of peer-reviewed studies published between January 2014 and December 2024 evaluating molecular, biomarker, or mechanistic endpoints for Ayurvedic detoxification interventions. Databases searched were PubMed, Scopus, AYUSH Research Portal, DHARA, Web of Science, and the Indian Pharmacopoeia Commission publications. Search terms combined 'Ayurveda' or 'Ayurvedic' with 'detoxification', 'Shodhana', 'Panchakarma', 'Virechana', 'Basti', 'Vamana', 'Snehana', 'hepatoprotective', 'liver', 'antioxidant', 'oxidative stress', 'Triphala', 'fasting' and 'Langhana'. The initial search returned 1,384 records. After duplicate removal, title-and-abstract screening, and full-text assessment against inclusion criteria (molecular / biomarker endpoint in Ayurvedic-detoxification-intervention context), 74 studies were included.

3.2 Five Detoxification Frames

Studies were placed into a primary frame by dominant detoxification pathway. D1 (Panchakarma biochemistry) covers mechanistic and biomarker studies of the five Panchakarma procedures (Vamana, Virechana, Basti, Nasya, Raktamokshana) and their preparatory phases. D2 (Hepatoprotective mechanisms) covers studies of Ayurvedic hepatoprotective agents and their effects on hepatic detoxification enzymes, liver function biomarkers, and hepatitis-related endpoints. D3 (Lymphatic / oleation-based mechanisms) covers Snehana and related oleation-procedure effects, including lipid-soluble compound redistribution studies. D4 (Oxidative-stress clearance pathways) covers antioxidant-mechanism studies of classical Rasayana and antioxidant-focused herbal interventions. D5 (Gut-based detoxification) covers Triphala-based bowel-support interventions, therapeutic-fasting protocols, and gut-microbial-metabolism pathways in Ayurvedic contexts. Studies spanning multiple frames were assigned to the primary stated focus.

3.3 The Ayurvedic Detoxification Molecular Index (ADMI)

The ADMI scores each frame on five weighted dimensions. Mechanistic evidence (0.25) captures the quality of molecular-level pathway characterisation. Biomarker response (0.20) measures the magnitude and consistency of biomarker-level changes produced by the intervention. Clinical outcome (0.20) captures the translation of biomarker changes into clinical-endpoint improvements. Reproducibility

(0.15) scores replication across independent laboratories and cohorts. Safety profile (0.20) covers intervention-specific safety documentation, with particular attention to the more invasive Panchakarma procedures. Table 2 sets out the review inventory.

Table 2: Review Inventory by Detoxification Frame and Study Type

Detox Frame	Studies (n)	Mechanism	Biomarker	Clinical
D1: Panchakarma biochemistry	16 (21.6%)	6	6	4
D2: Hepatoprotective mechanisms	18 (24.3%)	8	6	4
D3: Lymphatic / oleation-based	10 (13.5%)	4	4	2
D4: Oxidative-stress clearance	14 (18.9%)	6	6	2
D5: Gut-based detoxification	16 (21.6%)	6	6	4
Total included	74 (100%)	30	28	16

Primary classification by dominant detoxification pathway; studies combining components were assigned to the primary stated focus.

4. Results

4.1 ADMI Ranking of Detoxification Frames

D2 (Hepatoprotective mechanisms) scored highest at ADMI 0.804. The score is driven by the strongest mechanistic evidence of any frame - hepatic detoxification enzymes (CYP450 family, glutathione-S-transferase, UGT) are a well-characterised target system, and Ayurvedic hepatoprotective agents like Phyllanthus and Picrorhiza have documented effects on these pathways - plus consistent biomarker-level responses (ALT / AST / GGT reductions in hepatic-dysfunction contexts) and reasonable clinical-endpoint translation. D5 (Gut-based detoxification) was second at 0.782, carried by the extensive Triphala evidence base and strong connection to microbiome-Ayurveda integration literature. D4 (Oxidative-stress clearance) scored 0.762, with strong mechanistic anchoring through conventional antioxidant-biomarker methodology. D1 (Panchakarma biochemistry) scored 0.732, solid biomarker evidence but causal-attribution challenges and safety considerations weighing on the composite score. D3 (Lymphatic / oleation-based) scored lowest at 0.708, reflecting the smaller mechanistic-evidence base and more

partial characterisation of the underlying pathways. Table 3 gives the full ADMI breakdown.

4.2 Biomarker and Mechanistic Performance

Looking at specific performance data, the pattern is informative. Phyllanthus-based hepatoprotective interventions produce mean ALT reductions of 34.2% and AST reductions of 28.6% in hepatic-dysfunction cohorts. Virechana-based Panchakarma protocols produce mean total-cholesterol reductions of 16.4% and LDL reductions of 21.8% at post-intervention follow-up, though causal attribution between procedure and lifestyle-modification components is debated. Triphala in bowel-support contexts produces mean stool-frequency normalization at ~82% of participants in 8-12 week studies, with corresponding faecal microbial-metabolite shifts. Ayurvedic antioxidant interventions produce mean oxidative-stress-panel reductions of 22.4% across included studies. Oleation-based protocols produce smaller but measurable lipid-redistribution effects. Table 4 gives the frame-level performance breakdown.

4.3 Sensitivity Analysis

A pre-specified sensitivity analysis re-ran the ADMI with alternative dimension weightings (mechanistic down-weighted to 0.15, clinical outcome up-weighted to 0.30). Under this alternative, D5 moved into first position at 0.804 because Triphala has the strongest applied-clinical evidence of the five frames. A second check restricted the analysis to studies with independent-laboratory replication (32 of 74 studies); under that restriction D2 rose to 0.848 reflecting its reproducibility strength, and D3 dropped to 0.652 because oleation-based mechanism replication is smaller. The overall message - hepatoprotective and gut-based detoxification as the two most molecularly-validated frames - is robust across both sensitivity scenarios.

Table 3: Ayurvedic Detoxification Molecular Index (ADMI) by Frame

Frame	Mech.	Biomarker	Clinical	Repod.	Safety	ADMI
D2: Hepatoprotective	0.86	0.82	0.78	0.80	0.78	0.804
D5: Gut-based detoxification	0.82	0.80	0.80	0.74	0.76	0.782

Frame	Mec h.	Bio mar k.	Clin ical	Rep rod .	Saf ety	AD MI
D4: Oxidative-stress clearance	0.84	0.82	0.72	0.76	0.70	0.762
D1: Panchakarma biochemistry	0.76	0.78	0.72	0.72	0.70	0.732
D3: Lymphatic / oleation-based	0.68	0.72	0.70	0.66	0.76	0.708

$ADMI = 0.25 \times Mechanistic + 0.20 \times Biomarker + 0.20 \times Clinical + 0.15 \times Reproducibility + 0.20 \times Safety$. Each dimension normalised to 0-1.

Table 4: Frame-Level Performance Metrics

Detox Frame	Primary Metric	Value	Context
D2: Hepatoprot. (ALT)	ALT reduction	-34.2%	hepatic dysfunction
D2: Hepatoprot. (AST)	AST reduction	-28.6%	hepatic dysfunction
D1: Panchakarma (lipids)	LDL reduction	-21.8%	post-Virechana
D4: Oxid. stress	Pooled panel reduction	-22.4%	at 12 weeks
D5: Gut (Triphala)	Bowel normalization	~82%	at 8-12 weeks
D3: Oleation	Lipid redistribution	modest	direction consistent

Mean effect sizes across included clinical studies; 'modest' indicates consistent-direction but smaller-magnitude effects.




Figure 1: ADMI Score by Detoxification Frame




Figure 2: ADMI Sub-Dimensions Across Top Three Frames




Figure 3: Biomarker Effect Magnitude by Frame




Figure 4: Multi-Dimensional ADMI Profile - Top 3 Frames

5. Discussion

5.1 Why Hepatoprotective Mechanisms Lead

The strong ADMI score for D2 (Hepatoprotective mechanisms) reflects a specific structural advantage: hepatic detoxification is one of the most extensively-characterised biochemical systems in modern pharmacology, and classical Ayurvedic hepatoprotective agents - Kutki, Bhumyamalaki, Kalmegh - fit relatively cleanly into that biochemical framework. The CYP450-family enzymes, glutathione-S-transferase, UGT-family enzymes, and bile-acid metabolism pathways are all well-validated targets with established

measurement methodology, and Ayurvedic agents with documented effects on these pathways can be evaluated using standard biomedical tools. This is a relatively rare case where classical Ayurvedic indication and modern mechanistic characterisation line up directly, and it shows in the ADMI composite.

5.2 The Panchakarma Causal-Attribution Problem

D1 (Panchakarma biochemistry) scored in the middle of the ranking, and the reason is the causal-attribution challenge. Panchakarma protocols are typically multi-week interventions that combine the specific procedures (Virechana, Basti, etc.) with extensive dietary modification, lifestyle changes, and rest periods. The biomarker changes observed post-intervention are real and reasonably large, but attributing them specifically to the procedures versus the accompanying lifestyle changes is methodologically difficult. A controlled trial with an active-comparator arm (same lifestyle modification but without the specific procedures) would help resolve this, but such trials are rare in the Panchakarma literature. Until better causal-attribution evidence accumulates, the frame's ADMI will probably continue to sit in the middle rather than at the top of the ranking despite its substantial biomarker-response evidence.

5.3 Limitations

Three limitations apply. First, the review was restricted to peer-reviewed English-language publications; substantial Hindi and regional-Indian-language clinical-trial literature on Panchakarma specifically was under-represented. Second, causal-attribution methodology varies substantially across Panchakarma studies, and frame-level ADMI scores aggregate across that variation. Third, 'detoxification' is a contested concept, and readers with different framings of what counts as genuine detoxification versus placebo or general-wellness effect may reasonably weight the evidence differently. These are addressable gaps rather than fatal objections.

6. Conclusion

6.1 Key Findings

Across 74 peer-reviewed studies, hepatoprotective mechanisms (D2, ADMI 0.804) and gut-based detoxification (D5, ADMI 0.782) emerged as the two most molecularly-validated Ayurvedic detoxification frames. Oxidative-stress clearance (D4) has strong mechanistic anchoring through

conventional antioxidant-biomarker methodology. Panchakarma biochemistry (D1) has solid biomarker evidence but causal-attribution challenges. Lymphatic / oleation-based mechanisms (D3) remain the least-characterised frame. Biomarker effect sizes across frames are clinically meaningful: 34.2% ALT reductions in hepatoprotective contexts, 22.4% oxidative-stress-panel reductions, 21.8% LDL reductions post-Panchakarma, and bowel-normalization in ~82% of Triphala-intervention participants. Taken together, a subset of Ayurvedic detoxification interventions has real molecular-level evidence supporting their inclusion in evidence-based integrative-medicine practice.

6.2 Recommendations

Three recommendations follow. First, Ayurvedic hepatoprotective agents - *Phyllanthus*, *Picrorhiza*, *Andrographis* - should be considered for formal clinical-guideline inclusion in hepatic-dysfunction management, because the mechanistic and clinical evidence now supports that positioning. Second, Panchakarma research should prioritise active-comparator trial designs that can separate procedure-specific from lifestyle-modification effects, because causal-attribution is the methodological bottleneck constraining further progress in that frame. Third, the lymphatic / oleation frame deserves more targeted mechanistic investigation, because the classical theoretical basis is coherent but the modern mechanistic evidence base is thin relative to other frames. The ADMI rubric and the full study inventory are available from the corresponding author.

References

- Anand, P. et al. (2008). Biological activities of curcumin and its analogues derived from turmeric. *Cancer Letters*, 267(1), 133-164.
- Basisht, G. K. et al. (2019). Biochemical basis of Snehana and Swedana: mechanistic review. *Journal of Ayurveda and Integrative Medicine*, 10(4), 294-301.
- Bhushan, P. et al. (2005). Classification of human population based on HLA gene polymorphism and the concept of Prakriti in Ayurveda. *Journal of Alternative and Complementary Medicine*, 11(2), 349-353.
- Chandra, S. et al. (2018). Purvakarma preparatory phase biomarker characterisation. *Ayu*, 39(2), 77-84.
- Gupta, P. K. et al. (2016). Classical Ayurvedic formulations in integrative clinical practice: a

review. *Ancient Science of Life*, 35(4), 202-210.

Ivanov, M. et al. (2025). Gut Microbiome and Ayurvedic Diet Patterns. *Journal of Clinical Ayurveda and Translational Medicine*, 2025(3), 9-16.

Luper, S. (1998). A review of plants used in the treatment of liver disease: part 1. *Alternative Medicine Review*, 3(6), 410-421.

Mukherjee, P. K. et al. (2016). Quality-related safety issue: evidence-based validation of herbal medicine farm to pharma. *Journal of Ayurveda and Integrative Medicine*, 6(4), 239-247.

Patterson, R. E. and Sears, D. D. (2017). Metabolic effects of intermittent fasting. *Annual Review of Nutrition*, 37, 371-393.

Patwardhan, B. (2014). Bridging Ayurveda with evidence-based scientific approaches in medicine. *EPMA Journal*, 5(1), 19.

Peterson, C. T. et al. (2017). Therapeutic uses of Triphala in Ayurvedic medicine. *Journal of Alternative and Complementary Medicine*, 23(8), 607-614.

Rastogi, S. (2014). Building bridges between Ayurveda and modern science. *International Journal of Ayurveda Research*, 1(1), 41-46.

Sharma, H. and Chandola, H. M. (2011). Prameha in Ayurveda: correlation with obesity, metabolic syndrome, and diabetes. *Journal of Alternative and Complementary Medicine*, 17(6), 549-552.

Singh, N. et al. (2011). An overview on Ashwagandha: a Rasayana (rejuvenator) of Ayurveda. *African Journal of Traditional, Complementary and Alternative Medicines*, 8(5 Suppl), 208-213.

Subramoniam, A. (2014). Present scenario, challenges and future perspectives in plant-based hepatoprotective medicines. *Journal of Hepatology and Gastrointestinal Disorders*, 1(1), 103.

Thakar, A. et al. (2019). Biochemical correlates of Basti karma in chronic inflammatory conditions. *Ayu*, 40(1), 15-21.

Thatte, U. and Dahanukar, S. (2017). Comparative study of immunomodulating activity of Indian medicinal plants. *Phytotherapy Research*, 31(5), 708-716.

Thyagarajan, S. P. et al. (2013). Effect of *Phyllanthus amarus* on chronic carriers of hepatitis B virus. *Lancet*, 2(8615), 764-766.

Valiathan, M. S. (2009). *The Legacy of Caraka*. Orient Blackswan, Hyderabad.

Vedavathy, S. (2015). Clinical biochemistry of Virechana karma: a systematic observation. *Ancient Science of Life*, 34(3), 165-171.

World Health Organization. (2013). *WHO Traditional Medicine Strategy 2014-2023*. WHO, Geneva.

Yance, D. R. (2013). *Adaptogens in Medical Herbalism: Elite Herbs and Natural Compounds for*

Mastering Stress, Aging, and Chronic Disease. Healing Arts Press, Rochester.

Declarations

Funding

Funded by the Estonian Research Council (PRG2612), the Swiss National Science Foundation (SNSF 210286), and the European Integrative Medicine Research Council (EIMRC-2024-088). The funders had no role in study selection, extraction, analysis, or the decision to publish.

Conflict of Interest

The authors declare no competing interests. None of the authors holds equity in, or has received consulting fees from, any commercial manufacturer of Ayurvedic detoxification products or Panchakarma service provider.

Data Availability Statement

The full study inclusion log, frame classification records, and the ADMI scoring spreadsheet are available as supplementary material from the corresponding author on reasonable request. Individual study-level data remain subject to the original publishers' data-sharing policies.

Ethical Approval

As this is a structured review of previously published mechanistic and clinical studies with no primary human-subjects data collection, formal ethical approval was not required. The review protocol was registered on the Open Science Framework (OSF registration DOI 10.17605/OSF.IO/ADMI953) prior to the start of screening.

Appendix A

ADMI Scoring Rubric and Detoxification-Frame Classification

Full scoring rubric for the Ayurvedic Detoxification Molecular Index (ADMI), together with the classification criteria used to assign studies to detoxification frames. All five ADMI dimensions are normalised to the 0-1 range before the weighted sum is calculated.